Sofosbuvir; Velpatasvir; Voxilaprevir Patent Expiration
Sofosbuvir; Velpatasvir; Voxilaprevir is Used for treating chronic HCV infection in adults who have been previously treated with specific medications. It was first introduced by Gilead Sciences Inc
Sofosbuvir; Velpatasvir; Voxilaprevir Patents
Given below is the list of patents protecting Sofosbuvir; Velpatasvir; Voxilaprevir, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Vosevi |
US11338007 (Pediatric) | Combination formulation of three antiviral compounds | Dec 01, 2037 | Gilead Sciences Inc |
Vosevi | US10912814 | Combination formulation of three antiviral compounds | Jun 01, 2037 | Gilead Sciences Inc |
Vosevi | US11338007 | Combination formulation of three antiviral compounds | Jun 01, 2037 | Gilead Sciences Inc |
Vosevi |
US11116783 (Pediatric) | Combination formulation of two antiviral compounds | Jul 30, 2034 | Gilead Sciences Inc |
Vosevi | US9296782 | Inhibitors of hepatitis C virus | Jul 17, 2034 | Gilead Sciences Inc |
Vosevi | US11116783 | Combination formulation of two antiviral compounds | Jan 30, 2034 | Gilead Sciences Inc |
Vosevi |
US8575135 (Pediatric) | Antiviral compounds | May 16, 2033 | Gilead Sciences Inc |
Vosevi |
US8921341 (Pediatric) | Antiviral compounds | May 16, 2033 | Gilead Sciences Inc |
Vosevi |
US8940718 (Pediatric) | Antiviral compounds | May 16, 2033 | Gilead Sciences Inc |
Vosevi | US8575135 | Antiviral compounds | Nov 16, 2032 | Gilead Sciences Inc |
Vosevi | US8921341 | Antiviral compounds | Nov 16, 2032 | Gilead Sciences Inc |
Vosevi | US8940718 | Antiviral compounds | Nov 16, 2032 | Gilead Sciences Inc |
Vosevi | US9868745 | Antiviral compounds | Nov 16, 2032 | Gilead Sciences Inc |
Vosevi |
US8618076 (Pediatric) | Nucleoside phosphoramidates | Jun 11, 2031 | Gilead Sciences Inc |
Vosevi |
US9284342 (Pediatric) | Nucleoside phosphoramidates | Mar 13, 2031 | Gilead Sciences Inc |
Vosevi | US8618076 | Nucleoside phosphoramidates | Dec 11, 2030 | Gilead Sciences Inc |
Vosevi | US9284342 | Nucleoside phosphoramidates | Sep 13, 2030 | Gilead Sciences Inc |
Vosevi |
US7964580 (Pediatric) | NA | Sep 26, 2029 | Gilead Sciences Inc |
Vosevi |
US8633309 (Pediatric) | Nucleoside phosphoramidates | Sep 26, 2029 | Gilead Sciences Inc |
Vosevi |
US8889159 (Pediatric) | Compositions and methods for treating hepatitis C virus | Sep 26, 2029 | Gilead Sciences Inc |
Vosevi | US7964580 | NA | Mar 26, 2029 | Gilead Sciences Inc |
Vosevi | US8633309 | Nucleoside phosphoramidates | Mar 26, 2029 | Gilead Sciences Inc |
Vosevi | US8889159 | Compositions and methods for treating hepatitis C virus | Mar 26, 2029 | Gilead Sciences Inc |
Vosevi |
US8334270 (Pediatric) | NA | Sep 21, 2028 | Gilead Sciences Inc |
Vosevi |
US8580765 (Pediatric) | NA | Sep 21, 2028 | Gilead Sciences Inc |
Vosevi |
US8735372 (Pediatric) | NA | Sep 21, 2028 | Gilead Sciences Inc |
Vosevi |
US9085573 (Pediatric) | NA | Sep 21, 2028 | Gilead Sciences Inc |
Vosevi | US8334270 | NA | Mar 21, 2028 | Gilead Sciences Inc |
Vosevi | US8580765 | NA | Mar 21, 2028 | Gilead Sciences Inc |
Vosevi | US8735372 | NA | Mar 21, 2028 | Gilead Sciences Inc |
Vosevi | US8957046 | NA | Mar 21, 2028 | Gilead Sciences Inc |
Vosevi | US9085573 | NA | Mar 21, 2028 | Gilead Sciences Inc |
Vosevi | US9585906 | NA | Mar 21, 2028 | Gilead Sciences Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Sofosbuvir; Velpatasvir; Voxilaprevir's patents.
Latest Legal Activities on Sofosbuvir; Velpatasvir; Voxilaprevir's Patents
Given below is the list recent legal activities going on the following patents of Sofosbuvir; Velpatasvir; Voxilaprevir.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 8th Year, Large Entity | 13 Sep, 2023 | US9296782 |
Payment of Maintenance Fee, 8th Year, Large Entity | 03 Aug, 2022 | US8957046 |
Post Issue Communication - Certificate of Correction | 21 Jun, 2022 | US11338007 |
Recordation of Patent Grant Mailed Critical | 24 May, 2022 | US11338007 |
Patent Issue Date Used in PTA Calculation Critical | 24 May, 2022 | US11338007 |
Email Notification Critical | 05 May, 2022 | US11338007 |
Issue Notification Mailed Critical | 04 May, 2022 | US11338007 |
Email Notification Critical | 28 Apr, 2022 | US11338007 |
Mailing Corrected Notice of Allowability | 28 Apr, 2022 | US11338007 |
Corrected Notice of Allowability | 22 Apr, 2022 | US11338007 |